AR1001 Slows Decline in Monotherapy Group of Phase 3 Alzheimer Trial

Author profile image Aggregator
0 comments
Phase 3 POLARIS-AD results show AR1001 benefit on CDR-SB in a prespecified monotherapy population, but not in the overall early Alzheimer disease population.

Source: NeurologyLive Published 17 Nov 2026 Imported 18 Nov 2026 Relevancy: Not reviewed

Read the article